Plexision’s Pharmacokinetics (PK)/Pharmacodynamics (PD) solutions presented at Cambridge Healthtech...
Novel antibody-drug conjugates (ADC), some with dual cellular targets, are revolutionizing the delivery of potentially toxic chemotherapy or immunosuppressants to patients with malignancies or autoimmune diseases. Aimed at delivering drug or an innate immune effector cell, along with a biospecific antibody to the diseased tissue, these novel constructs target cellular receptors whose expression may differ between species and tissues. Such differences pose challenges to designing preclinical studies to predict safe dose-escalation or toxicity in early development, or to optimizing post-marketing efficacy of a newly approved drug. These challenges support greater use of human cell-based disease simulations for PK/PD modeling, and characterization of individual differences in drug effect from the outset. In such simulations, the need for surrogate markers of disease and response to therapy has never been greater.
Intro the presentation can be found on CHI's site here. Additional details will be posted when available.
Plexision uses PK/PD modeling in (human) cell-based disease models to predict effective drug concentration ranges for immunological disorders.
Cambridge Healthtech Institute (CHI) is the leader in conference and event development and management for the life sciences industry.